Skip to main content

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Trial Status: Active

To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.

Inclusion Criteria

  • Male or female patients age ≥ 18 years of age at the time of informed consent
  • Ability to provide and understand written informed consent prior to any study procedures
  • Histologically or cytologically confirmed metastatic UM
  • No prior systemic therapy in the metastatic or advanced setting
  • No prior local, liver-directed therapy; prior surgical resection of oligometastatic liver disease is allowed
  • Prior neoadjuvant or adjuvant therapy is allowed provided administered in the curative setting in patients with localized disease

Exclusion Criteria

  • Impaired baseline organ function as evaluated by out-of-range laboratory values
  • History of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies
  • Clinically significant cardiac disease or impaired cardiac function
  • Presence of symptomatic or untreated central nervous system (CNS) metastases
  • Active infection requiring systemic antibiotic therapy
  • Known history of human immunodeficiency virus infection (HIV)
  • Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
  • Malignant disease, other than that being treated in this study
  • Patients receiving systemic steroid therapy or any other systemic immunosuppressive medication. Local steroid therapies are acceptable
  • History of adrenal insufficiency, pneumonitis, interstitial lung disease, or inflammatory bowel disease
  • Major surgery within 2 weeks of the first dose of study drug
  • Radiotherapy within 2 weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited field
  • Use of hematopoietic colony-stimulating growth factors (eg, G-CSF, GM-CSF, M-CSF) ≤ 2 weeks prior to start of study drug
  • Pregnant, likely to become pregnant, or lactating women


Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Status: ACTIVE
Palo Alto
Stanford Cancer Institute Palo Alto
Status: ACTIVE


University of Colorado Hospital
Status: ACTIVE


University of Miami Miller School of Medicine-Sylvester Cancer Center
Status: ACTIVE


Emory University Hospital / Winship Cancer Institute
Status: ACTIVE


Northwestern University
Status: ACTIVE
University of Chicago Comprehensive Cancer Center
Status: ACTIVE


Iowa City
University of Iowa / Holden Comprehensive Cancer Center


Brigham and Women's Hospital
Status: ACTIVE
Dana-Farber Cancer Institute
Status: ACTIVE
Massachusetts General Hospital Cancer Center
Status: ACTIVE
Contact: Ryan Joseph Sullivan
Phone: 617-724-4000


Saint Louis
Siteman Cancer Center at Washington University
Status: ACTIVE

New York

Roswell Park Cancer Institute
New York
Memorial Sloan Kettering Cancer Center
Status: ACTIVE
NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center
Status: ACTIVE

North Carolina

Duke University Medical Center
Status: ACTIVE


Ohio State University Comprehensive Cancer Center
Status: ACTIVE


Oklahoma City
University of Oklahoma Health Sciences Center
Status: ACTIVE


Thomas Jefferson University Hospital
Status: ACTIVE
University of Pittsburgh Cancer Institute (UPCI)
Status: ACTIVE

This Phase II study is designed to evaluate the safety and efficacy of IMCgp100 compared with Investigator's Choice (dacarbazine, ipilimumab or pembrolizumab) in HLA-A*0201 positive adult patients with advanced UM treated in the first line setting with no prior systemic or liver-directed chemo-, radio- or immune-therapy administered in the advanced setting (prior surgical resection of liver metastases and adjuvant systemic therapy are acceptable). Comparison of the IMCgp100 efficacy results in this Phase II study will be made with the concurrently randomized arm (Investigator's Choice) with a primary endpoint of overall survival (OS) and secondary efficacy endpoints of progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), and disease control rate (DCR).

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Immunocore Ltd

  • Primary ID IMCgp100-202
  • Secondary IDs NCI-2017-00590
  • ID NCT03070392